<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13327">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01968707</url>
  </required_header>
  <id_info>
    <org_study_id>EM-012760</org_study_id>
    <nct_id>NCT01968707</nct_id>
  </id_info>
  <brief_title>In-vivo Efficacy Study of Patient Pre-operative Preps</brief_title>
  <official_title>Assessment of the Antimicrobial Efficacy of 3M CHG/IPA Preoperative Skin Preparation Against Resident Human Skin Flora on the Abdominal and Inguinal Regions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>3M</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>3M</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the antimicrobial efficacy of the 3M CHG/IPA Prep
      on skin flora of the abdomen and inguinal regions of human subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>A 2-log per cm2 bacterial reduction on the abdomen and a 3-log per cm2 bacterial reduction on the inguinal region.</measure>
    <time_frame>10 minutes post-product application</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin flora does not return to baseline on the abdomen and inguinal region.</measure>
    <time_frame>6 hours post-product application</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by Skin Irritation score and Adverse Events</measure>
    <time_frame>10 minute to 6 hour post-product application</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Bacterial Reduction on Skin Flora Post-product Application</condition>
  <arm_group>
    <arm_group_label>ChloraPrep CHG/IPA Hi-Lite Orange Tint</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% normal saline with applicator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3M CHG/IPA Tint 10.5mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70% 10.5 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3M CHG/IPA Tint 26mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70% 26 mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHG 2% / IPA 70%</intervention_name>
    <arm_group_label>ChloraPrep CHG/IPA Hi-Lite Orange Tint</arm_group_label>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_label>3M CHG/IPA Tint 10.5mL</arm_group_label>
    <arm_group_label>3M CHG/IPA Tint 26mL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects of any race

          -  Subjects in good general health

          -  Minimum skin flora baseline requirements on abdomen and groin

        Exclusion Criteria:

          -  Any tattoos, scars, breaks in the skin, or any form of dermatitis, or other skin
             disorders (including acne) on the applicable test areas

          -  Topical antimicrobial exposure within 14 days prior to screening and treatment days

          -  Use of systemic or topical antibiotics, steroid medications, or any other products
             known to affect the normal microbial flora of the skin within 14 days prior to
             screening and treatment days
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muhammad H Bashir, MD, CCRP</last_name>
    <role>Principal Investigator</role>
    <affiliation>MICROBIOTEST</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muhammad H Bashir, MD, CCRP</last_name>
    <phone>703-925-0100</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Microbiotest</name>
      <address>
        <city>Sterling</city>
        <state>Virginia</state>
        <zip>20164</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad H Bashir, MD, CCRP</last_name>
      <phone>703-925-0100</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 24, 2014</lastchanged_date>
  <firstreceived_date>October 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>surgical prep</keyword>
  <keyword>CHG</keyword>
  <keyword>IPA</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
